Navigation Links
Roundworm unlocks pancreatic cancer pathway

Chapel Hill, NC The National Cancer Institute estimates that more than 43,000 Americans were diagnosed with pancreatic cancer last year and more than 36,000 died from the disease. Despite advances in genetic science showing that the Ras oncogene is mutated in virtually all pancreatic cancers, scientists have been frustrated by the complexity of the signaling pathways in humans, which make it difficult to pinpoint potential therapeutic targets.

In a study published today in the Cell Press journal Developmental Cell, a team of researchers led by Channing Der, PhD, Distinguished Professor of Pharmacology at UNC-Chapel Hill, took a step back to a simpler organism a common roundworm and made a discovery about how the Ras oncogene chooses a signaling pathway and how the consequences of that choice play out in cellular development a key issue in cancer, which is characterized by uncontrolled cell growth.

Der, who is also a member of UNC Lineberger Comprehensive Cancer Center, explains, "In humans the cell signaling pathways are very complex; there are more than 20 different downstream partners beyond the two proteins we study Raf and RalGEF that Ras can choose to interact with. In C. elegans, there is only one of each protein. That made it easier for us to identify how Ras chooses a partner to 'dance' with and what are the critical events in the subsequent cell development that promote cancer."

"We found an elegant mechanism by which Ras switches partners and showed that the choice leads to very different fates for the cell. Now we can go back to the human pancreatic cancer cell and ask whether similar mechanisms are at work in determining how Ras causes pancreatic cancer," he adds.

Scientists often study simpler organisms to tease out genetic and cellular activity that might be almost impossible to map in humans. "Worms' cells actually share a great deal of functional overlap with human cells. However, while there may be one mechanism in a simple organism like a worm, there are multiple mechanisms at work in humans. It's a great thing for us as people, because there is a great deal of redundancy in our biological systems that helps them self-repair and function better, but it makes it a lot harder to study what's going on at a basic level," Der notes.

"If this signaling works in a similar way in humans, the C. elegans model may be very powerful for helping us find new therapeutic targets for pancreatic cancer," he concludes.


Contact: Ellen de Graffenreid
University of North Carolina School of Medicine

Related biology news :

1. Biochemist unlocks genes role in breast-tumor growth
2. DNA sequencing unlocks relationships among flowering plants
3. BIO 2009 -- R&D session: New stem cell research unlocks unknown therapies
4. Landmark study unlocks stem cell, DNA secrets to speed therapies
5. Missing molecules hold promise of therapy for pancreatic cancer
6. UNC team discovers promising target for new pancreatic cancer treatments
7. Glucosamine causes the death of pancreatic cells
8. Pancreatic cancers use fructose, common in the Western diet, to fuel their growth
9. TGen-Asuragen partner to advance pancreatic cancer research
10. Predicting prognosis and treatment response in a subset of pancreatic cancer patients
11. Soft drink consumption may increase risk of pancreatic cancer
Post Your Comments:
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
(Date:10/23/2015)... DUBLIN , Oct. 23, 2015 Research ... of the "Global Voice Recognition Biometrics Market 2015-2019" ... --> --> The global voice recognition ... during 2014-2019. --> ... 2015-2019, has been prepared based on an in-depth market ...
(Date:10/22/2015)...  Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter ended September 30, 2015.  --> ... $4.0 million, a decrease of 33% compared to $6.0 million in ... of 2015 was $2.2 million, or $0.10 per diluted share, which ... same period a year ago.  --> ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
Breaking Biology Technology: